PT-141: Uses, Evidence, Safety, Dosing, and How It Works

PT-141, also called bremelanotide or Vyleesi, is a melanocortin-receptor agonist peptide studied mainly for hypoactive sexual desire disorder in premenopausal women. It appears to act through central nervous-system pathways rather than by directly increasing genital blood flow. Evidence includes multiple randomized trials, but safety, dosing, and fit require clinician review.

What it is

PT-141 is a peptide drug also called bremelanotide, and Vyleesi is a brand name tied to the same active ingredient in clinical research. It belongs to a class called melanocortin-receptor agonists, which means it activates melanocortin pathways involved in sexual response and other nervous-system signaling 4.

In plain terms, PT-141 is not a blood-flow drug in the same way sildenafil is. The published trials mainly studied bremelanotide in premenopausal women with hypoactive sexual desire disorder, female sexual dysfunction, or female sexual arousal disorder 4 10.

Names: PT-141, bremelanotide, and Vyleesi

• PT-141: common peptide name used in patient searches and earlier research.
• Bremelanotide: the generic active-ingredient name used in most clinical trial papers 4.
• Vyleesi: a brand name people may see when searching bremelanotide information.
• Melanocortin-receptor agonist: the drug class named in human studies of bremelanotide 7.

Mechanism of action

PT-141 works through melanocortin receptor pathways, which are signaling routes in the brain and nervous system. The human studies describe bremelanotide as a melanocortin-receptor agonist, but a clinical trial title alone does not prove every downstream step in humans 7.

Melanocortin-receptor agonism

A receptor agonist is a molecule that turns on a receptor. Bremelanotide has been studied as a melanocortin-receptor agonist in sexual arousal and desire conditions, which supports a central nervous-system mechanism rather than a purely vascular one 7 10.

How PT-141 differs from blood-flow medications

Sildenafil, known by the brand name Viagra, is commonly discussed as a blood-flow medication for erectile dysfunction. In contrast, PT-141 has been studied for subjective sexual response and desire-related outcomes, including in premenopausal women and in one randomized trial of men who had not responded to sildenafil 2 7.

Evidence

Evidence grade: A — two or more human randomised controlled trials. The main evidence base includes randomized phase 3 trials in premenopausal women with hypoactive sexual desire disorder, a randomized dose-finding trial in female sexual dysfunction, an earlier randomized study in female sexual arousal disorder, and a randomized study in men who had not responded to sildenafil 4 10 7 2.

A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.

What the human research studied

The RECONNECT phase 3 program evaluated bremelanotide in premenopausal women with hypoactive sexual desire disorder, and later subgroup analyses examined prespecified and integrated findings from those studies 4 3. A separate phase 2b program evaluated dose-ranging approaches, and responder analyses looked at how participants responded within that program 10 5.

What the evidence does not prove

The retrieved evidence does not show that PT-141 is a universal libido medication for every adult. It also does not prove that compounded PT-141 nasal spray has the same outcomes as the bremelanotide products and routes studied in trials; compounded formulations do not have FDA-evaluated outcomes data.

Evidence in men and sildenafil nonresponders

One randomized, double-blind, placebo-controlled study evaluated bremelanotide as a salvage approach in men who had not responded to sildenafil 2. That is useful evidence, but it is much narrower than the larger female sexual dysfunction and hypoactive sexual desire disorder research base 4 10.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-02.

Reported dosing ranges

Published PT-141 dosing should not be copied as self-treatment. The retrieved studies include dose-finding and phase 3 research, but the source records provided here do not give full patient-level dosing instructions that can be safely applied to an individual reader 10 5 4.

Why dosing should not be copied from studies

Study dosing is chosen for research rules, not for your personal health history. A clinician needs to consider blood pressure, cardiovascular risk, current medications, side-effect risk, and whether the symptom pattern matches the studied populations 1 11.

Dose form, timing, and supervision considerations

The retrieved evidence pool includes bremelanotide trials, safety analyses, ambulatory blood-pressure monitoring, and ethanol coadministration research 1 11 12. Those sources support a careful, supervised approach rather than self-directed use from a research-chemical supplier.

Legal status

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-02. See the full legal-status tracker for every compound we follow.

Safety

PT-141 safety has been evaluated across a clinical development program, but that does not mean it is safe for everyone. Safety papers and randomized studies specifically examined adverse events, blood-pressure effects, and tolerability with ethanol coadministration 1 11 12.

Nausea, flushing, headache, and other reported adverse events

The safety profile paper for bremelanotide across the clinical development program is the best retrieved source for overall adverse-event reporting 1. Commonly discussed patient-facing side effects include nausea, flushing, and headache; a clinician should also review less common risks and reasons treatment may not fit.

Blood pressure and heart-rate findings

Blood pressure matters with PT-141 because a randomized study used ambulatory blood-pressure monitoring to assess the melanocortin-receptor agonist bremelanotide 11. If a person has hypertension, cardiovascular disease, fainting episodes, or uses blood-pressure medication, that history should be reviewed before any treatment decision.

Alcohol coadministration study findings

A phase 1 randomized, placebo-controlled, double-blind study assessed the safety and tolerability of bremelanotide when coadministered with ethanol in healthy male and female participants 12. That type of study helps frame alcohol-related safety questions, but it does not make alcohol use risk-free for every patient.

Risks of unregulated supply

A major safety issue is where the substance comes from. “Research use only” material is not medical care; it may raise identity, sterility, impurity, and dosing-accuracy concerns because it is not dispensed through a clinician-reviewed patient process.

Who should ask a clinician before considering PT-141?

• Anyone with high or unstable blood pressure, because blood-pressure monitoring has been studied with bremelanotide 11.
• Anyone with heart disease, chest pain, fainting, or complex cardiovascular history.
• Anyone taking medications that affect blood pressure, sexual function, nausea, or mood.
• Anyone who is pregnant, trying to become pregnant, or breastfeeding.
• Anyone using alcohol around the time of sexual activity, because ethanol coadministration has been specifically studied 12.

Interactions

Medication review is part of PT-141 safety, especially when blood pressure, alcohol, or sexual-function medications are involved. The retrieved evidence includes specific studies on ambulatory blood-pressure monitoring and ethanol coadministration, but it does not provide a complete interaction map for every drug or supplement 11 12.

Why medication review matters before use

Sexual-function symptoms can be affected by antidepressants, blood-pressure drugs, hormone changes, sleep, stress, alcohol, and relationship factors. The patient-experience study from the RECONNECT program can help describe how participants experienced treatment, but it should not replace a full medical review 8.

Cardiovascular risk and blood-pressure medication considerations

Because ambulatory blood-pressure monitoring was important enough to study in randomized bremelanotide research, people with blood-pressure conditions should treat this as a clinician-review issue, not a supplement-style purchase 11. This is especially important if multiple medications affect blood pressure or heart rate.

How to obtain it legally

The legitimate care process for PT-141 starts with a health history, medication review, and clinician decision. At Chia, we offer PT-141 nasal spray and the Spark protocol through an online evaluation reviewed by a licensed US provider; a prescription requires a medical evaluation and is never guaranteed.

PT-141 at Chia: nasal spray with clinician review

Chia’s PT-141 offering is nasal spray, with plans currently starting at $159/month. If a provider determines treatment is clinically appropriate, medication is compounded in the US by a state-licensed 503A compounding pharmacy and shipped to the patient’s door; compounded medications are not FDA-approved.

How Chia’s online evaluation works

1. 1You complete a short online health questionnaire about your goals, medical history, medications, and safety factors.
2. 2A licensed US provider reviews whether treatment may be appropriate.
3. 3If prescribed, dosing is provider-guided and adjusted through the patient portal when needed.
4. 4If medication is dispensed, it is prepared by a state-licensed 503A compounding pharmacy and shipped to your door.

What Chia can and cannot promise

We can provide a structured medical review and a licensed care path when PT-141 fits. We cannot promise that a prescription will be written, that treatment will work for a specific person, or that side effects will not happen.

Why research-chemical vendors are not medical care

A research-chemical website is not a clinician evaluation, a prescription review, or a licensed pharmacy relationship. For any peptide used by people, the safer axis is licensed care versus unlicensed supply: identity, sterility, impurities, and follow-up all matter.

How does PT-141 compare with Viagra?

PT-141 and Viagra are different tools, and the retrieved PT-141 evidence should not be read as a head-to-head proof that one is better. One randomized trial studied bremelanotide in men who had not responded to sildenafil, while the larger PT-141 evidence base centers on premenopausal women with desire-related diagnoses 2 4.

Some patients who ask about PT-141 are also exploring broader longevity or energy protocols. Those are separate goals: Chia’s NAD+, sermorelin, and Foundation Longevity pages explain different treatment categories, forms, and care processes.

Keep reading

Peptides

Can You Buy PT-141 on Amazon? What to Know Before Ordering

Peptides

PT-141 Peptide (Bremelanotide): How It Works, Uses, and Safety

Peptides

How to Buy PT-141 Peptide Safely: Prescription Options, Risks, and What to Ask